Magnetically softened iron oxide (MSIO) nanofluid and its application to thermally-induced heat shock proteins for ocular neuroprotection.
Magnetically softened iron oxide (MSIO) nanofluid, PEGylated (Mn0.5Zn0.5)Fe2O4, was successfully developed for local induction of heat shock proteins (HSPs) 72 in retinal ganglion cells (RGCs) for ocular neuroprotection. The MSIO nanofluid showed significantly enhanced alternating current (AC) magnetic heat induction characteristics including exceptionally high SLP (Specific Loss Power, > 2000 W/g). This phenomenon was resulted from the dramatically improved AC magnetic softness of MSIO caused by the magnetically tailored Mn(2+) and Zn(2+) distributions in Fe3O4. In addition, the MSIO nanofluid with ultra-thin surface coating layer thickness and high monodispersity allowed for a higher cellular uptake up to a 52.5% with RGCs and enhancing "relaxation power" for higher AC heating capability. The RGCs cultured with MSIO nanofluid successfully induced HSPs 72 by magnetic nanofluid hyperthermia (MNFH). Moreover, it was interestingly observed that systematic control of "AC magnetically-induced heating up rate" reaching to a constant heating temperature of HSPs 72 induction allowed to achieve maximized induction efficiency at the slowest AC heating up rate during MNFH. In addition to in-vitro experimental verification, the studies of MSIO infusion behavior using animal models and a newly designed magnetic coil system demonstrated that the MSIO has promising biotechnical feasibility for thermally-induced HSPs agents in future glaucoma clinics.
Department of Electrical Engineering, University of South Carolina, Columbia, SC, 29208, USA. Electronic address: bae4@cec.sc.edu.
Seongtae
S
Bae
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Jin Wook
JW
Jeoung
Department of Electrical and Computer Engineering, National University of Singapore, Singapore, 117576, Singapore.
Minhong
M
Jeun
Department of Electrical Engineering, University of South Carolina, Columbia, SC, 29208, USA.
Jung-Tak
JT
Jang
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Joo Hyun
JH
Park
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Yu Jeong
YJ
Kim
Department of Electrical Engineering, University of South Carolina, Columbia, SC, 29208, USA; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Kwan
K
Lee
Biomedical Research Institute, Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Department of Neurosurgery, Seoul National University College of Medicine Seoul, 110-744, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Minkyu
M
Kim
Biomedical Research Institute, Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Department of Neurosurgery, Seoul National University College of Medicine Seoul, 110-744, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Jooyoung
J
Lee
Biomedical Research Institute, Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Department of Neurosurgery, Seoul National University College of Medicine Seoul, 110-744, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Hey Min
HM
Hwang
Biomedical Research Institute, Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Department of Neurosurgery, Seoul National University College of Medicine Seoul, 110-744, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
Sun Ha
SH
Paek
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, 110-744, South Korea. Electronic address: kihopark@snu.ac.kr.
Ki Ho
KH
Park
D000818:Animals; D002460:Cell Line; D002470:Cell Survival; D002478:Cells, Cultured; D005901:Glaucoma / Q000378:metabolism / Q000628:therapy*; D006360:Heat-Shock Proteins / Q000378:metabolism*; D006979:Hyperthermia, Induced / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000627:therapeutic use*; D008297:Male; D000066829:Neuroprotection; D051381:Rats; D017207:Rats, Sprague-Dawley; D012165:Retinal Ganglion Cells / Q000166:cytology / Q000378:metabolism*
D006360:Heat-Shock Proteins; D058185:Magnetite Nanoparticles
(Mn(0.5)Zn(0.5))Fe(2)O(4) nanoparticles; Heat shock proteins; Magnetic nanofluid hyperthermia (MNFH); Magnetically softened iron oxide (MSIO); Ocular neuroprotection